Baxter posts 20% jump in 1st-qtr profit

19 April 2009

Shares in Baxter International rose 3.2% on April 16, after the US health care firm said that its first-quarter 2009 profit jumped 19.9%  year-on-year to $518.0 million, or $0.83 per share.

During the period, sales fell 2% to $2.82 billion. Analysts polled by  Thomson Reuters had predicted profit of $0.83 per share on revenues of  $2.87 billion.

According to the Illinois-based firm, its strong downturn-defying  performance was partly thanks to robust underlying fundamentals across  the portfolio and improved margins, driven by operational leverage and  favorable business and product mix.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight